Review/Advances in Neurological Therapeutics (2018). Dementia

Abstract

Dementia affects over 46 million people in the world with a rapidly increasing prevalence. No fundamental treatment for AD has been established, and novel experimental studies are under investigation. This progress has led to the development of numerous therapeutic strategies in the clinical testing. Immunotherapy against Aβ has been pursued extensively as a therapeutic approach to AD and other dementias, and several other promising trials are currently ongoing.

In 2018, these outcomes including solanezumab, verubecestat, LMTM, idalopirdine, pimavanserin and so on have been reported. This review overviewed recent advances in these larger clinical researches in dementia.